Should I buy or sell Opthea stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Opthea in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OPT shares. View OPT analyst ratings or view top-rated stocks .

What is Opthea's stock price target for 2024?

2 Wall Street research analysts have issued 12 month price targets for Opthea's shares. Their OPT share price targets range from $12.00 to $16.00. On average, they expect the company's stock price to reach $14.00 in the next twelve months. This suggests a possible upside of 324.2% from the stock's current price. View analysts price targets for OPT or view top-rated stocks among Wall Street analysts .

How have OPT shares performed in 2024?

Opthea's stock was trading at $2.95 at the start of the year. Since then, OPT shares have increased by 11.9% and is now trading at $3.30. View the best growth stocks for 2024 here .

What guidance has Opthea issued on next quarter's earnings?

Opthea issued an update on its FY 2023 earnings guidance on Tuesday, January, 23rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $47.5 million-$47.5 million.

Opthea (OPT) raised $161 million in an IPO on Friday, October 16th 2020. The company issued 9,300,000 shares at a price of $17.26 per share. Citigroup and SVB Leerink acted as the underwriters for the IPO and Oppenheimer & Co. and Truist Securities were co-managers.

How do I buy shares of Opthea?

Shares of OPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:OPT

Opthea (OPT) Stock Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Free OPT Stock Alerts

$3.30

-0.10 (-2.94%)

(As of 05:21 PM ET)

Compare

Today's Range: $3.20
▼
$3.40
50-Day Range: $2.83
▼
$4.14
52-Week Range: $1.60
▼
$4.42

Volume: 3,723 shs
Average Volume: 24,288 shs
Market Capitalization: $192.72 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $14.00

Get Opthea alerts:

Opthea MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 324.2% Upside
$14.00 Price Target
Short Interest: Healthy
0.22% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.51
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.57) to ($2.25) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.96 out of 5 stars

Medical Sector

584th out of 911 stocks

Biological Products, Except Diagnostic Industry

95th out of 150 stocks

3.5

Analyst's Opinion

Consensus Rating
Opthea has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Opthea has received no research coverage in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
0.22% of the outstanding shares of Opthea have been sold short.
Short Interest Ratio / Days to Cover
Opthea has a short interest ratio ("days to cover") of 4.9.
Change versus previous month
Short interest in Opthea has recently decreased by 5.77%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Opthea does not currently pay a dividend.
Dividend Growth
Opthea does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for OPT.

1.4

News and Social Media Coverage

News Sentiment
Opthea has a news sentiment score of -0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Opthea this week, compared to 1 article on an average week.
Search Interest
1 people have searched for OPT on MarketBeat in the last 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Opthea insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.20% of the stock of Opthea is held by insiders.
Percentage Held by Institutions
55.95% of the stock of Opthea is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Opthea are expected to grow in the coming year, from ($2.57) to ($2.25) per share.

See Top Rated MarketRank™ Stocks Here

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About Opthea Stock (NASDAQ:OPT)

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

OPT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

OPT Stock News Headlines

April 13, 2024 | americanbankingnews.com

FY2024 EPS Estimates for Opthea Limited Lowered by Analyst (NASDAQ:OPT)

April 8, 2024 | globenewswire.com

Opthea Appoints John Han, PharmD, as VP Medical Affairs

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

April 5, 2024 | nasdaq.com

Opthea Limited American Depositary Shares (OPT)

April 4, 2024 | globenewswire.com

Opthea to Participate in the 23ʳᵈ Annual Needham Virtual Healthcare Conference

April 3, 2024 | msn.com

Why A2 Milk, Lindsay Australia, Meridian Energy, and Opthea shares are falling today

April 3, 2024 | globenewswire.com

Opthea Appoints Sujal Shah to the Board of Directors

April 3, 2024 | investorplace.com

7 Growth Stocks to Buy to Outperform the Nasdaq Index

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

March 19, 2024 | globenewswire.com

Opthea to Host Key Opinion Leader Event on Sozinibercept (OPT-302) in Wet Age-Related Macular Degeneration on April 3, 2024

March 6, 2024 | msn.com

End in sight as Opthea looks to be key player in US$10 billion wet AMD market

March 5, 2024 | globenewswire.com

Opthea to Participate in the Leerink Partners Global Biopharma Conference

February 28, 2024 | globenewswire.com

Opthea Reports Half-Year Financial Results and Business Updates

February 22, 2024 | au.finance.yahoo.com

Opthea Limited (OPT)

February 20, 2024 | finanznachrichten.de

Opthea Limited: Opthea Appoints Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor

February 19, 2024 | globenewswire.com

Opthea Appoints Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor

February 14, 2024 | finanznachrichten.de

Opthea Limited: Opthea Completes Enrollment in First Pivotal Trial with Sozinibercept

February 14, 2024 | finance.yahoo.com

Opthea Completes Enrollment in First Pivotal Trial with Sozinibercept

February 14, 2024 | globenewswire.com

Opthea Completes Enrollment in First Pivotal Trial with Sozinibercept

December 27, 2023 | msn.com

Why Is Retinal Diseases-Focused Opthea Stock Trading Higher Today?

December 27, 2023 | msn.com

Opthea to receive $35M commitment and additional $50M funding

December 27, 2023 | marketwatch.com

Opthea Limited ADRs Rise 31% on Raised Funding

December 27, 2023 | finance.yahoo.com

Opthea to Receive US$35M Commitment and Additional US$50M Funding

December 16, 2023 | msn.com

Opthea Limited - ADR (OPT) Price Target Increased by 7.41% to 6.39

December 1, 2023 | finance.yahoo.com

Opthea to Present at the FLORetina 2023 Congress

November 27, 2023 | msn.com

Opthea Limited - ADR (OPT) Price Target Increased by 9.06% to 5.95

November 9, 2023 | finance.yahoo.com

Opthea to Present at the Jefferies 2023 London Healthcare Conference

See More Headlines

Receive OPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Opthea and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/19/2024
Fiscal Year End: 6/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:OPT
CUSIP: N/A
CIK: 1815620
Web: www.opthea.com
Phone: 61-3-9826-0399
Fax: N/A
Employees: 24
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $14.00
High Stock Price Target: $16.00
Low Stock Price Target: $12.00
Potential Upside/Downside: +328.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: $110,000.00
Price / Sales: 1,736.07
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.10) per share
Price / Book: -32.70

Miscellaneous

Outstanding Shares: 58,400,000
Free Float: 56,526,000
Market Cap: $190.97 million
Optionable: Not Optionable
Beta: 1.19

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Dr. Megan Baldwin M.A.I.C.D. (Age 49)
MAICD, Ph.D., Founder, Chief Innovation Officer & Executive Director
Comp: $599.73k
Ms. Judith J. Robertson B.A. (Age 63)
M.B.A., Chief Commercial Officer
Comp: $588.59k
Ms. Karen Adams CPA (Age 52)
VP of Finance & Company Secretary
Comp: $305.14k
Dr. Frederic Guerard M.S. (Age 51)
Pharm.D., Chief Executive Officer
Mr. Peter F. Lang M.B.A. (Age 51)
Chief Financial Officer
Ms. Sarika Gulhar Ph.D.
Executive Director of Human Resources
Dr. Michael Gerometta Ph.D. (Age 59)
Head of Chemistry, Manufacturing & Controls Development
Comp: $127.66k
Mr. Bruno Gagnon BPHARM (Age 55)
M.Sc., Senior Vice President of Global Clinical Operations
Dr. Kenneth Sall
Chief Medical Officer
Dr. Fang Li Ph.D.
Senior Vice President of Regulatory Affairs

Key Competitors

View All Competitors

Institutional Ownership

OLD Mission Capital LLC
Bought 12,220 shares on 2/15/2024
Ownership: 0.021%

View All Institutional Transactions

OPT Stock Analysis - Frequently Asked Questions

Should I buy or sell Opthea stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Opthea in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OPT shares.
View OPT analyst ratings or view top-rated stocks.
What is Opthea's stock price target for 2024?: 2 Wall Street research analysts have issued 12 month price targets for Opthea's shares. Their OPT share price targets range from $12.00 to $16.00. On average, they expect the company's stock price to reach $14.00 in the next twelve months. This suggests a possible upside of 324.2% from the stock's current price.
View analysts price targets for OPT or view top-rated stocks among Wall Street analysts.
How have OPT shares performed in 2024?: Opthea's stock was trading at $2.95 at the start of the year. Since then, OPT shares have increased by 11.9% and is now trading at $3.30.
View the best growth stocks for 2024 here.
What guidance has Opthea issued on next quarter's earnings?: Opthea issued an update on its FY 2023 earnings guidance on Tuesday, January, 23rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $47.5 million-$47.5 million.

When did Opthea IPO?: Opthea (OPT) raised $161 million in an IPO on Friday, October 16th 2020. The company issued 9,300,000 shares at a price of $17.26 per share. Citigroup and SVB Leerink acted as the underwriters for the IPO and Oppenheimer & Co. and Truist Securities were co-managers.
How do I buy shares of Opthea?: Shares of OPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:OPT) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial